Suppr超能文献

利用随机突变文库高效鉴定对蛋白酶抑制剂耐药的人类免疫缺陷病毒 1 型突变体。

Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.

机构信息

UCLA School of Medicine, Los Angeles, CA 90095, USA.

出版信息

Antimicrob Agents Chemother. 2011 Nov;55(11):5090-8. doi: 10.1128/AAC.00687-11. Epub 2011 Aug 29.

Abstract

Emergence of drug-resistant mutant viruses during the course of antiretroviral therapy is a major hurdle that limits the success of chemotherapeutic treatment to suppress human immunodeficiency virus type 1 (HIV-1) replication and AIDS progression. Development of new drugs and careful patient management based on resistance genotyping data are important for enhancing therapeutic efficacy. However, identifying changes leading to drug resistance can take years of clinical studies, and conventional in vitro assays are limited in generating reliable drug resistance data. Here we present an efficient in vitro screening assay for selecting drug-resistant variants from a library of randomly mutated HIV-1 strains generated by transposon-directed base-exchange mutagenesis. As a test of principle, we screened a library of mutant HIV-1 strains containing random mutations in the protease gene by using a reporter T-cell line in the presence of the protease inhibitor (PI) nelfinavir (NFV). Analysis of replicating viruses from a single round of infection identified 50 amino acid substitutions at 35 HIV-1 protease residue positions. The selected mutant viruses showed specific resistance to NFV and included most of the known NFV resistance mutations. Therefore, the new assay is efficient for identifying changes leading to drug resistance. The data also provide insights into the molecular mechanisms underlying the development of drug resistance.

摘要

在抗逆转录病毒治疗过程中,耐药突变病毒的出现是一个主要障碍,限制了化学治疗抑制人类免疫缺陷病毒 1 型(HIV-1)复制和艾滋病进展的成功。开发新的药物和基于耐药基因型数据的谨慎患者管理对于提高治疗效果非常重要。然而,确定导致耐药性的变化可能需要多年的临床研究,并且传统的体外检测在产生可靠的耐药性数据方面受到限制。在这里,我们提出了一种有效的体外筛选检测方法,用于从转座子指导的碱基交换诱变产生的随机突变 HIV-1 株文库中选择耐药变体。作为原理的验证,我们在存在蛋白酶抑制剂(PI)奈非那韦(NFV)的情况下,使用报告 T 细胞系筛选了含有蛋白酶基因随机突变的突变 HIV-1 株文库。对一轮感染中复制病毒的分析鉴定了 HIV-1 蛋白酶 35 个残基位置的 50 个氨基酸取代。所选的突变病毒对 NFV 表现出特异性耐药性,并且包括大多数已知的 NFV 耐药突变。因此,新的检测方法可有效识别导致耐药性的变化。这些数据还提供了对耐药性发展的分子机制的深入了解。

相似文献

本文引用的文献

2
HIV-1 protease mutations and protease inhibitor cross-resistance.HIV-1 蛋白酶突变与蛋白酶抑制剂交叉耐药性。
Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.
6
New developments in HIV drug resistance.艾滋病毒耐药性的新进展。
J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i37-40. doi: 10.1093/jac/dkp258.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验